Gender disparities in lipid-lowering therapy in cardiovascular disease: Insights from a managed care population

Journal of Women's Health

Volumn 25, Issue 7, 2016, Pages 697-706

  Rodriguez, Fatima ^a   Olufade, Temitope O ^b   Ramey, Dena R ^b   Friedman, Howard S ^c   Navaratnam, Prakash ^c   Heithoff, Kim ^b   Foody, JoAnne M ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Data Solutions LLC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHARLSON COMORBIDITY INDEX; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SEX DIFFERENCE; STATISTICS; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; EPIDEMIOLOGY; FACTUAL DATABASE; HEALTH CARE DISPARITY; HEALTH INSURANCE; HYPERCHOLESTEROLEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HEALTHCARE DISPARITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 84978419136     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2015.5282     Document Type: Article

References (39)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014; 129: e28-e292
2. Jarvie JL, Foody JM. Recognizing and improving health care disparities in the prevention of cardiovascular disease in women. Curr Cardiol Rep 2010; 12: 488-496
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-2828
4. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311-318
5. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-282
6. Cholesterol Treatment Trialists Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
8. Rodriguez F, Olufade T, Heithoff K, Friedman HS, Navaratnam P, Foody JM. Frequency of high-risk patients not receiving high-potency statin (from a large managed care database). Am J Cardiol 2015; 115: 190-195
9. Cholesterol Treatment Trialists Collaborators, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385: 1397-1405
10. Turnbull F, Arima H, Heeley E, et al. Gender disparities in the assessment and management of cardiovascular risk in primary care: The AusHEART study. Eur J Cardiovasc Prev Rehabil 2011; 18: 498-503
11. Chou AF, Scholle SH, Weisman CS, Bierman AS, Correade-Araujo R, Mosca L. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007; 17: 120-130
12. Vimalananda VG, Miller DR, Palnati M, Christiansen CL, Fincke BG.Gender disparities in lipid-lowering therapy among veterans with diabetes. Womens Health Issues 2011; 21: S176-S181
13. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934
14. Coffman DL. Estimating causal effects in mediation analysis using propensity scores. Struct Equ Modeling 2011; 18: 357-369
15. Jo B, Stuart EA, Mackinnon DP, Vinokur AD. The use of propensity scores in mediation analysis. Multivariate Behav Res 2011; 46: 425-452
16. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429-1433
17. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Wahlberg E. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2009; 16: 39-46
18. Morrell J, Zeymer U, Baumgartner I, et al. Differences in management and outcomes between male and female patients with atherothrombotic disease: Results from the REACH Registry in Europe. Eur J Cardiovasc Prev Rehabil 2011; 18: 270-277
19. Naicker K, Liddy C, Singh J, Taljaard M, Hogg W. Quality of cardiovascular disease care in Ontario's primary care practices: A cross sectional study examining differences in guideline adherence by patient sex. BMC Fam Pract 2014; 15: 123
20. Kim C, Kerr EA, Bernstein SJ, Krein SL. Gender disparities in lipid management: The presence of disparities depends on the quality measure. Am J Manag Care 2006; 12: 133-136
21. Zhang R, Zhao L, Liang L, Xie G, Wu Y. Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy. Lipids Health Dis 2012; 11: 59
22. Santos RD, Waters DD, Tarasenko L, et al. Low-and highdensity lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J 2009; 158: 860-866
23. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, Davidson MH. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey. Am Heart J 2006; 152: 976-981
24. Dallongevillle J, De Bacquer D, Heidrich J, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart 2010; 96: 1744-1749
25. Bird CE, Fremont AM, Bierman AS, et al. Does quality of care for cardiovascular disease and diabetes differ by gender for enrollees in managed care plans? Womens Health Issues 2007; 17: 131-138
26. Cooke CE, Hammerash WJ, Jr. Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease: An analysis of patient data from a Marylandbased health maintenance organization. Clin Ther 2006; 28: 591-599
27. Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372
28. Kim C, Hofer TP, Kerr EA. Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model. J Gen Intern Med 2003; 18: 854-863
29. Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA. Fifteen-year trends in awareness of heart disease in women: Results of a 2012 American Heart Association national survey. Circulation 2013; 127: 1254-1263, e1-29
30. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010; 48: 196-202
31. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: A meta-analysis. Am Heart J 2013; 165: 665-678, 678 e661
32. Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern Italian primary care: Can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One 2014; 9: e102146
33. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23: 1182-1186
34. Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering inwomen with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 2008; 94: 434-439
35. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-1028
36. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-408
37. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep 2010; 12: 322-330
38. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: A guideline from the American Heart Association. Circulation 2011; 123: 1243-1262
39. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007; 49: 1230-1250